PIN107 Past trends and current challenges in the hepatitis c reimbursement landscape: is history repeating itself?  by Griffiths, E.A. & Noble, L.A.
A246  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
equate to reimbursement and treatment uptake, as therapies must also convinc-
ingly demonstrate cost-effectiveness as well as justifying budget impact.
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OBJECTIVES: The world’s worst outbreak of Ebola occurred in 2014 with 21,296 
cases and 8,429 deaths reported in total. The first case of Ebola was recorded on 
30th September by Centers for Disease Control and Prevention (CDC) in the US. 
Pharmacists can play an important role in treating Ebola patients. The aim of this 
study is to assess knowledge and attitude about Ebola among U.S. pharmacy stu-
dents. METHODS: This was a cross sectional survey study. An Ebola questionnaire 
was distributed among third year pharmacy students in a private university in 
the U.S. before and after delivering an educational Ebola seminar based on the 
CDC and World Health Organization Ebola fact sheet N103. The questionnaire com-
prised of 33 questions was divided into three components: demographics (3), Ebola 
knowledge (25) and attitude about Ebola (5). Paired t test and McNemar test were 
employed using SPSS version 21. RESULTS: A total of 103 pharmacy students partici-
pated in the survey. The study population had a highly significant increase in Ebola 
related knowledge about species (p< 0.001), incubation period (p< 0.001), diagnosis 
(p< 0.001), vaccination (p< 0.05), treatment (p< 0.001), complications (p< 0.001) and 
immunity (p< 0.01). Also, a significant number of study participants had a positive 
attitude about treating Ebola patients and believed that Ebola patients should be 
kept isolated (p< 0.05) and communities should actively participate in preventing 
the spread of Ebola (p< 0.05). CONCLUSIONS: Students, upon becoming PharmD 
professionals can apply the knowledge acquired through this study for effectively 
treating patients. Focused seminars are a valuable tool to improve student aware-
ness of infectious disease.
PIN109
ProjeCt sKANt - study of ANtIbIotIC PresCrIPtIoN IN CommuNIty IN 
slovAKIA
Antlova K.1, Snopkova M.1, Foltan V.2
1Faculty of Pharmacy Comenius University, Bratislava, Slovak Republic, 2Faculty of Pharmacy, 
Comenius University, Bratislava, Slovak Republic
OBJECTIVES: Antibiotics in clinical practice in Slovakia are often indicated unneces-
sarily and without proper differential diagnosis that differentiate viral form bacte-
rial etiologic agents. Due to the frequent indications of antibiotics in praxis are 
consumption trends increasing, there is greater financial burden an the health 
care as well as we can observe unjustified consumption. In consequence the resist-
ance of microorganisms to antibiotics is increasing. METHODS: Our work aims 
to give an image of the current prescribing behaviour of physicians involved in 
the project SKANT – The School of Antibiotic Therapy. It evaluates trends in anti-
biotic prescription in the treatment of respiratory diseases, the etiology of infec-
tions, antibiotic administration merits focused on Slovakia during first quarter of 
2013. Implementation by validate questionnaire study of prescribing in general 
practitioners for adults and general practitioners for children and adolescents in 
Slovakia. RESULTS: According to the evaluated data there is high consumption 
in the group of penicillins and macrolides. The unjustified prescription of mac-
rolides 24.58% due to allergy of patients to penicillins 4.67%. In these respiratory 
diseases, antibiotics were most frequently indicated: Sinusitis acuta (79.47%), 
Tonsilopharyngitis acuta (69.78%), Bronchitis acuta and Tracheobronchitis acuta 
(68.80%) The use of microbiological and biochemical tests were observed in 26.5% 
of patients. In 73.5% not used any of these tests. CONCLUSIONS: Analysis of treat-
ment with antimicrobial drugs for acute respiratory diseases confirmed the current 
trend of increasing prescription in Slovakia. Excessive consumption of antibiotics 
often leads to unwanted spread of antimicrobial resistance and the ineffectiveness 
of existing drugs to fight infections. The solution unfavorable situation is repeated 
audits of prescribing antimicrobial drugs. Based on the results of our study we sug-
gest prepare educational training for laic and professional public.
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OBJECTIVES: Skin and soft tissue infections (SSTI) are among the most common 
hospital infections, and represent a heterogeneous range of infection types with 
numerous treatment options. While recent research has begun to characterize 
treatment patterns and associated outcomes, little is known about country-specific 
practice patterns. The purpose of this analysis was to characterize current prac-
tice patterns in the treatment of SSTIs in select European countries. METHODS: A 
retrospective analysis was conducted using Arlington Medical Resources’ (AMR’s) 
Hospital Antibiotic Market audit January-June 2013. The audit is comprised of data 
elements including patient demographics, diagnosis, therapy sequence, switching, 
and concomitance, hospital and intensive care unit, length of stay, discharge drug, 
and drug costs. RESULTS: A sample of adult inpatients with SSTIs projected to 
national volume in Germany (n= 427,516), United Kingdom (UK; n= 292,265), Italy 
(n= 199,588) and Spain (195,084) were included for analysis. Demographic charac-
teristics were similar across countries; diabetes and heart disease were the most 
common comorbidities. Practice patterns varied considerably; the most common 
first-line treatment was ampicillin/sulbactam (22.1%) in Germany, flucloxacillin 
(31.9%) in UK, ceftriaxone (10.7%) in Italy, and amoxicillin/clavulanate (21.2%) in 
Spain. MRSA rates across all SSTIs were 3.5%, 4.9%, 3.3%, and 3.4% in Germany, UK, 
pneumococcal vaccination coverage and factors associated with receiving pneu-
mococcal vaccination in U.S. adults with high-risk conditions encompassed by the 
ACIP recommendation. METHODS: This retrospective observational cohort study 
included commercially-insured adults aged 19-64 years with newly-diagnosed 
chronic medical conditions from 2007-2010. Outcomes of interest include pneu-
mococcal vaccination coverage and time from initial diagnosis to pneumococcal 
vaccination. RESULTS: Among 300,556 U.S. adults with high-risk conditions, 30% 
had their condition diagnosed by primary care physicians. On average, these adults 
visited pharmacy, doctor’s office, outpatient hospital, inpatient hospital and emer-
gency department 38.3, 27.3, 6.6, 0.4, and 1.4 times, respectively, during an average 
2.6 years of follow-up. Nevertheless, overall pneumococcal vaccination coverage was 
only 6.9%. Coverage was highest in patients with HIV (32.1%), followed by diabetes 
(11.2%), chronic lung disease (8.5%), asplenia (6.8%), chronic renal disease (5.9%), 
chronic heart disease (5.7%), cochlear implant (4.4%), cancer (4.2%), chronic liver 
disease (3.7%), alcoholism (2.5%), and transplant (2.0%). Among those who received 
pneumococcal vaccination, the majority was vaccinated in the physician’s office 
(99%); average time from initial diagnosis to vaccination was 469 days, ranging 
from 198 days for HIV to 576 days for chronic liver disease. Multivariable logistic 
regression showed that adults who were older, initially diagnosed by primary care 
physicians, received influenza vaccination, had more conditions or more healthcare 
encounters were more likely to receive pneumococcal vaccination. CONCLUSIONS: 
Pneumococcal vaccination coverage in adults with high-risk conditions was far 
below the Healthy People 2020 objective. Findings suggest missed opportunities 
continue and better interventions needed to improve pneumococcal vaccination 
during healthcare encounters for this vulnerable population.
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OBJECTIVES: Adults are increasingly receiving vaccinations outside of traditional 
doctor’s office setting. This study aimed to examine, from the patient’s perspective, 
drivers and behaviors of adult vaccinations across various settings. METHODS: 
A cross-sectional, self-administered, online survey was conducted in U.S. nation-
ally representative adults aged at least 19 years who received either influenza, 
pneumococcal, or zoster vaccine within the past 6 months. The survey explored 
attitudes, preferences, and behaviors of adults vaccinated at various settings. 
Descriptive and bivariate analyses were applied to analyze patients’ responses 
by each vaccine and setting. RESULTS: Among 1,178 qualified respondents, 46.0% 
were vaccinated at doctor’s office, 37.1% at pharmacy, and the remaining at other 
clinical or community settings. Other than doctor’s office or pharmacy, the most 
common alternative setting to receive vaccination was workplace for influenza 
vaccine (15.5%), and hospital/emergency room for pneumococcal (9.3%) and zoster 
(5.5%) vaccines. Adults were more likely to know about the vaccines offered at 
the doctor’s office directly from physicians (68.6%), while the majority of adults 
knew about vaccines offered at the pharmacy from seeing signs in the pharmacy 
(37.8%). Consistent across all three vaccines, the main drivers for selecting vac-
cination settings were “This location accepts my insurance”, followed by “This is 
a location I already visit for other reason” and “I was able to vaccinate without an 
appointment”. The primary reason for choosing to vaccinate at the doctor’s office 
was “This is a location I already visit for other reasons”, for pharmacy was “The 
location accepts my insurance”, and for other settings was “Lower out-of-pocket 
cost”. Among all respondents, 17.7% received two or more vaccines concurrently, 
with convenience and healthcare provider recommendation reported as the main 
drivers. CONCLUSIONS: Findings suggest opportunities to improve adult vacci-
nation at traditional and non-traditional settings, and highlight importance of 
healthcare provider recommendation in adult vaccination.
PIN107
PAst treNds ANd CurreNt ChAlleNges IN the hePAtItIs C 
reImbursemeNt lANdsCAPe: Is hIstory rePeAtINg Itself?
Griffiths E.A., Noble L.A.
HERON Commercialization, PAREXEL, London, UK
OBJECTIVES: In 2011, the introduction of boceprevir and telaprevir was hailed as a 
breakthrough in the hepatitis C (HCV) treatment paradigm, but these treatments 
were not widely adopted due to cost and safety concerns. 4 years on, the intro-
duction of newer, more effective therapies (e.g. simeprevir and sofosbuvir) has re-
revolutionized the HCV space. However, cost concerns continue to limit the number 
of patients being treated with new medicines. To inform future submissions, HCV 
reimbursement decisions across 5 HTA agencies were assessed and the underlying 
rationale examined. METHODS: NICE, SMC, PBAC, CADTH, and TLV were searched 
for guidance on HCV medicines between December 2010 and December 2014. 
Recommendations for and rationale behind each decision were extracted. RESULTS: 
Boceprevir and telaprevir had each been assessed 6 times across the different agen-
cies including resubmissions: PBAC initially rejected both, then restricted both 
dependent on reduced price at resubmission; CADTH also restricted both depend-
ent on reduced price. Submissions were accepted in-line with the label by the other 
agencies. Reasons for rejection/restriction of boceprevir and telaprevir included 
cost-effectiveness concerns, uncertain efficacy in some patient populations, and 
safety concerns. Simeprevir had been assessed 4 times with 1 in development: 
CADTH and TLV restricted simeprevir due to uncertainty over cost-effectiveness 
and efficacy in some genotypes; PBAC and SMC accepted simeprevir. Sofosbuvir 
had been assessed 4 times with 1 in development: PBAC rejected sofosbuvir due to 
unacceptable cost-effectiveness and high budget impact; CADTH and TLV restricted 
sofosbuvir dependent on reduced price; SMC accepted sofosbuvir. CONCLUSIONS: 
Despite higher cure rates achieved with newer treatment options, cost-effectiveness 
concerns remain the primary reason for rejection or restriction of HCV therapies 
by HTA agencies. Manufacturers should not assume that high clinical efficacy will 
